We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| BTG | LSE:BGC | London | Ordinary Share | GB0001001592 | ORD 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 387.50 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 387.50 | GBX |
BTG (BGC) Share Charts1 Year BTG Chart |
|
1 Month BTG Chart |
Intraday BTG Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 13/3/2014 | 15:26 | BTG....a blockbuster in the making | 20,366 |
| 26/11/2009 | 11:04 | Only worth 33.5p on fundamentals | 31 |
| 23/9/2009 | 06:04 | **Ј 50 MILLION CASH PILE:WHAT CREDIT CRUNCH?** | 134 |
| 11/6/2009 | 23:15 | BTG Company transformation on the way? | 6 |
| 28/9/2007 | 09:34 | BGC Charts | 3 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 25/5/2012 13:02 by aquila2001 RNSTIDMBGC BTG PLC 25 May 2012 BTG to present at the Jefferies Global Healthcare Conference London, UK, 25 May 2012: BTG plc (LSE: BGC), the specialist healthcare company, today announces that Louise Makin, CEO, will be presenting at the Jefferies Global Healthcare Conference in New York, US on Thursday, 7 June at 9.00am EDT (New York time), 2.00pm BST (London time). The presentation will be uploaded to the BTG's website in the Investor/Results and Presentations area shortly after the presentation has concluded to ensure access for anyone unable to attend in person. |
Posted at 21/5/2012 18:41 by superbarnet A share price can be slashed even when good results are reported. It all depends on the analysts' expectations. I am delighted at the performance today as the price was little changed. The graph shows the long term direction and i will be adding over the next few weeks. |
Posted at 21/5/2012 10:45 by a1ord53 I am doubting that Astra Zeneca will be interested to buy BTG: 1 They have already license agreement for CytoFab . 2 The rest of BTG pipeline is not for Astra's strategy. 3 I think that BTG will be looking around to buy , like LM mentioned at presentation today. So IMO there will be no bid for BTG soon. SP hopefully will be slowly growing after consolidation. PS1 Jefferies has reiterated its buy recommendation and 410p target price for specialist healthcare company BTG (LSE: BGC.L - news) after the firm's full-year results this morning. PS2 BTG (LSE: BGC.L - news) : Finncap raises to hold from sell ANYBODY KNOWS WHAT RECOMMENDATIONS ISSUED OTHER BROKERS ? THANKS IN ADVANCE ))) I think results didnt impress buyers unfortunately despite better market today ((( |
Posted at 24/4/2012 18:21 by doctor 69 Overall btg is undervalued , but given how poor the other large pharmas pipelines are btg will with time rise up . We have seen a steady share price rise , but the share price rise is too slow for the comming events . Whilst recently the price started to appreciate zytiga it has not factored in the beads, the ms treatment, certainly not varisolve or anthing for cytofab .I keep thinking about our local vascular surgeons preferring to inject foam than strip veins and it makes me think if USA . The share price will be much higher as it month we realise how big varisolve is worth . Just wait till profits will be in the hundreds of millions and btg reaches. £ 10b capitalisation . This is really possible over next 3 yrs . |
Posted at 30/3/2012 14:23 by gregmorg I am in this one for the long term although it already has been a long time to date! The news flow has been good yet time and time again brokers' research notes suggest that every bit of good news is already discounted. For instance Edison suggested that positive news on the next two Phase 3 trials on Varisolve, due in 2012, is already discounted in their valuation.(and they do paid for research). Admittedly they had an asset valuation of over a pound north of here but not reflecting in any way the sorts of huge cash flow that should result from Varisolve let alone other products in the stable. Another broker I came across has also got a lower asset valuation, actually one lower than the current share price which completely flummoxed me.Several times these "experts" state that the Varisolve trials are already discounted in the share price(I would love to see the maths on that one!) although not good news on AZD9773 where it seems some are more positive as a result of earlier trial data. That rather intrigued me. All one can do is listen and learn(and be a bit irritated!) but been in this game too long to take most outside "experts in this field too seriously. Nevertheless rather fed up with this waiting for good news and when it comes the share price flips up only to lose all the gain, and often more, as the bears get to grips. Value does eventually show thru on all stocks but I do wonder whether the investor PR approach here just does not understand the market or is just too cautious for even us long term holders. We shall see. |
Posted at 12/2/2012 19:55 by bargainbob SpyderAnother 2 billion could be added to the company share price if it makes 200-225 million a year profit. Thats around a £10 a share. This does not include the Sepis factor although high risk at the moment which would be the real share price multiplier. £20 -£30 adder. Suspect V to hit the £10 target in 3 years . As for Sepis we wait and see. |
Posted at 30/1/2012 19:39 by toffeeman4 Agree Waterloo, either the board keeps the share price rising or a predator will do it for them. This latest Varisolve news is very welcome, feels very positive and will underpin the share price. Should a predator move in, we must be looking at close to a £5 take out price. However I feel we could well be looking at that level in the next 12-18 months as further hopefully positive news comes through on Varisolve. At some point surely analysts will start to factor into their figures the question of dividends. There is also elevation to the FTSE to look forward to which will mean further increase in share price. Varisolve could well deliver both these. Then there is CytoFab, which would totally transform the company. |
Posted at 30/1/2012 14:48 by thekobbler One explanation is that today's news was probably anticipated, hence the recent steady share price rise recently. There is a generalisation with phase III clinical trials, that no news is good news. Therefore as there had been no "negative" news up to the expected reporting milestone, then the trial must be going ok. In fact I think it seems to have performed even better than OK, so can only see these continuing to climb as the news/risk reduction sinks in. IIRC the possible worldwide sales for Varisolve are in the region of $450m per annum within 5 years from FDA approval. The current share price does not reflect this enormous potential, even with a 90% risk estimate. |
Posted at 28/12/2011 08:50 by toffeeman4 Just to add my thoughts to recent posts. No one has mentioned future dividends. Should Varisolve make it to market then dividends will come into play driving the share price.Should both Varisolve and CytoFab both fail, I think probably £2 is a bottom to share price which is supported by current turnover of approx £165m and cash balances. Were Varisolve make it to market I would look for a capitalisation around £1.6bn+, based on additional sales of £150m pa. CytoFab is a complete gamechanger if approved. BTG would get 25% of sales together with cash of £150m from milestone. Again this would impact on future dividends. I have no idea what the beads business is worth, anyone? As for takeover prospects, you can bet that BTG is being seriously looked at by others. I've said it before, Shire's share price continues to rise and could be used to acquire BTG. AZ could take out the whole company just purely for CytoFab and sell the rest on, or make an offer for CytoFab too good to refuse, special dividend for us shareholders? Exciting times ahead, probably with a few blips along the way. Lets hope it all comes off. |
Posted at 17/11/2011 15:56 by a1ord53 Broker Peel Hunt, which rates the shares a "buy", responded to the update by cranking up its price target from 300p to 320p. "We see four near-term drivers of growth emerging," explained Peel Hunt analyst Dr. Paul Cuddon. "Zytiga/Campath royalties are beginning to offset the loss of Benefix (which may be extended into H2 [second half] pending legal discussions); direct control of CroFab and DigiFab in the US provides a channel to leverage. Varisolve is nearing the end of its development phase with encouraging anecdotal feedback and the beads business looks primed for strong growth subject to increased R&D investment," Dr. Cuddon said. "We believe the latter two opportunities are each capable of £100m in high margin sales," he added. finnCap, however, believes that the share price is up with events, and rates the shares a "hold". "With key triggers for the shares (Varisolve and CytoFab clinical results) occurring towards the middle of next year, we rate the shares a Hold and retain our 285p price target," said finnCap analyst, Keith Redpath. The share price rose 2.99% to 295.8p by 13:19. NR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
